BioinvestGPT:
The world's most powerful and reliable clinical prediction AI for any drug and any disease

  • 95% proven accuracy of prospective data-independent real-world clinical benefit predictions with clear rationale
  • 2,000,000+ human-equivalent virtual patients for any human disease
  • 140+ billion USD healthcare investments are being enhanced and derisked by BioinvestGPT
  • 1800+ virtual clinical trials prospectively validated to meet arbitrarily rigorous standard of proof
  • 10x higher success rate and 10% R&D cost for curing cancer and dementia


Performance Dashboard
intro-bg-virtualpatients
Millions
clinically validated human-equivalent virtual patients

Adjust filters or
to view products

Compelling Data Present the Most Powerful and Reliable Clinical Prediction AI



Development Phase
Back
Glossary
Development Phase
Development Phase
Preclinical
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
Phase 3
Phase 3
Registration
Registration
Show All
Preclinical
Phase 1
Phase 2
Phase 3
Therapeutic Area
Back
Glossary
Therapeutic Area
Therapeutic Area.
Neoplasms
Neoplasms
Rare Diseases/NMH
Rare Diseases
Inflammation &Immunology
Inflammation and Immunology.
Metabolic and Cardio and Renal
Metabolic and Cardio and Renal
Oncology
This Therapeutic Area specializes in therapies that target cancer.
Vaccines
Vaccines.
Show All
First-In-Class
Best-In-Class
Oncology
Immunology
Neurology
Metabolic &Cardio & Renal
Eye & Skin & Musculoskeletal
Infections
Back
Glossary
Drug Class
Drug Class
First-In-Class
A novel modality that has never been approved by a pharmaceutical regulatory agency (e.g., the FDA).
Best-In-Class
An approved or investigational drug that is being tested to potentially treat another related condition. For example, drugs approved for the treatment of one type of cancer may be tested to see if they are potentially effective across another type of cancer.
Show All
First-In-Class
Best-In-Class
Drug Modality
Back
Glossary
Drug Modality
Drug Modality
Biologic
Biologic
Small Molecule
Small Molecule
Vaccine
Vaccine
Show All
Conjugate
Degrader
Multispecific Antibody
siRNA
Cell Therapy
Peptide
Protein
Small Molecule
Biologic
Medical Device
mRNA
Microbiome
Vaccine
Formulation
Gene Therapy
Prediction Status
Back
Glossary
Prediction Status
Designation of whether a prediction is validated as a "correct prediction", invalidated as a "missed" prediction, or not validated as of yet as a "pending prediction.”
Correct Prediction
A prospective prediction is correct if any of the following is true: (a) The technical clinical prediction matches the corresponding clinical readout for phase 1b/phase 2a non-oncology/obesity/AD clinical trials. (b) The commercial clinical prediction matches the corresponding clinical readout for phase 2b/phase 3 clinical trials and phase 1b/phase 2a oncology/obesity/AD clinical trials. More precisely, a “SUCCESS commercial clinical prediction” is called correct if it is numerically better than (placebo-adjusted delta is preferred whenever there is a placebo control arm in the real clinical trial. There is no placebo control arm in many phase 1b/phase 2a real clinical trials so change from baseline value would be used instead) the SoC (The SoC could be pre-specified by the trial sponsor in the real head-to-head clinical trials. If there is no active control arm in the real clinical trials, then SoC would be pre-specified per bespoke instructions from specialist clients or per default selections by BioinvestGPT for our virtual head-to-head clinical trials to generate commercial clinical predictions) on registrational efficacy & toxicity endpoints (they are usually primary endpoints for phase 2b/phase 3 real clinical trials and secondary/exploratory endpoints for phase 1b/phase 2a real clinical trials). (c) The downward post-readout stock price movement corresponds to our OVERPRICED label to a company in the prediction, regardless of the actual readouts or our technical/commercial clinical predictions.
Missed Prediction
A prospective prediction is missed if any of the following is true: (a) The technical clinical prediction doesn't match the corresponding clinical readout for phase 1b/phase 2a non-oncology/obesity/AD clinical trials. (b) The commercial clinical prediction doesn't match the corresponding clinical readout for phase 2b/phase 3 clinical trials and phase 1b/phase 2a oncology/obesity/AD clinical trials. More precisely, a “SUCCESS commercial clinical prediction” is called correct if it is numerically better than (placebo-adjusted delta is preferred whenever there is a placebo control arm in the real clinical trial. There is no placebo control arm in many phase 1b/phase 2a real clinical trials so change from baseline value would be used instead) the SoC (The SoC could be pre-specified by the trial sponsor in the real head-to-head clinical trials. If there is no active control arm in the real clinical trials, then SoC would be pre-specified per bespoke instructions from specialist clients or per default selections by BioinvestGPT for our virtual head-to-head clinical trials to generate commercial clinical predictions) on registrational efficacy & toxicity endpoints (they are usually primary endpoints for phase 2b/phase 3 real clinical trials and secondary/exploratory endpoints for phase 1b/phase 2a real clinical trials). (c) The upward post-readout stock price movement corresponds to our OVERPRICED label to a company in the prediction, regardless of the actual readouts or our technical/commercial clinical predictions.
Pending Prediction
A prospective prediction is pending if there is no public announcement of the corresponding clinical readout as of today.
Show All
Correct Prediction
Missed Prediction
Indications
Back
Show All
Current Prediction
Correct Prediction
Missed Prediction
Prediction
Indication
PIndication
Indication
Indication
modality Name
Back
Glossary
Drug modality
Drug Modality
Show All
Back
All Filters
Reset
Development Phase
Preclinical
Phase 1
Phase 2
Phase 3
Therapeutic Area
Oncology
Immunology
Neurology
Metabolic &Cardio & Renal
Rare Diseases
Infections
Drug Class
First-In-Class
Best-In-Class
Drug Modality
Small Molecule
Biologic
Vaccine
Prediction Status
Correct Prediction
Missed Prediction
Back
Search Products
Back
result found
Development Phase
  • Phase 1
  • Phase 2
  • Phase 3
Therapeutic Area
Drug Class
Drug Modality
Prediction Status
results found

results found

Indications

Development Phase

  • Phase 1
  • Phase 2
  • Phase 3

Therapeutic Area

Drug Class

Drug Modality

Prediction Status

Prediction Performance

2024YTD (99% CI)

0

True Positive

0

True Negative

0

False Positive

0

False Negative

0

Total Validated Prediction

Filters

Drug Class

Drug Modality

Therapeutic Area

Development Phase

Prediction Status

No Search Results Found!!

Adjust filters or
to view products

CLINICAL TRIAL CONDITION CERTIFIED PROSPECTIVE PREDICTION PREDICTION VALIDATION PREDICTION RESULT

Glossary

Development Phase
Development Phase
Preclinical
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
Phase 3
Phase 3
Registration
Registration
Therapeutic Area
Our key areas of research, bucketed by disease type, biology area, or therapy type.
Neoplasms
Rare Diseases/NMH
Rare Diseases/NM
Inflammation &Immunology
Immunology
Internal Medicine
Oncology
This Therapeutic Area specializes in therapies that target cancer.
Vaccines
Vaccines
Drug Class
Drug Class
First-In-Class
A novel modality that has never been approved by a pharmaceutical regulatory agency (e.g., the FDA).
Best-In-Class
An approved or investigational drug that is being tested to potentially treat another related condition. For example, drugs approved for the treatment of one type of cancer may be tested to see if they are potentially effective across another type of cancer.
Drug Modality
Drug Modality
Biologic
Biologic
Small Molecule
Small Molecule
Vaccine
Vaccine
Prediction Status
Designation of whether a prediction is validated as a "correct prediction", invalidated as a "missed" prediction, or not validated as of yet as a "pending prediction.”
Correct Prediction
A prospective prediction is correct if any of the following is true: (a) The technical clinical prediction matches the corresponding clinical readout for phase 1b/phase 2a non-oncology/obesity/AD clinical trials. (b) The commercial clinical prediction matches the corresponding clinical readout for phase 2b/phase 3 clinical trials and phase 1b/phase 2a oncology/obesity/AD clinical trials. More precisely, a “SUCCESS commercial clinical prediction” is called correct if it is numerically better than (placebo-adjusted delta is preferred whenever there is a placebo control arm in the real clinical trial. There is no placebo control arm in many phase 1b/phase 2a real clinical trials so change from baseline value would be used instead) the SoC (The SoC could be pre-specified by the trial sponsor in the real head-to-head clinical trials. If there is no active control arm in the real clinical trials, then SoC would be pre-specified per bespoke instructions from specialist clients or per default selections by BioinvestGPT for our virtual head-to-head clinical trials to generate commercial clinical predictions) on registrational efficacy & toxicity endpoints (they are usually primary endpoints for phase 2b/phase 3 real clinical trials and secondary/exploratory endpoints for phase 1b/phase 2a real clinical trials). (c) The downward post-readout stock price movement corresponds to our OVERPRICED label to a company in the prediction, regardless of the actual readouts or our technical/commercial clinical predictions.
Missed Prediction
A prospective prediction is missed if any of the following is true: (a) The technical clinical prediction doesn't match the corresponding clinical readout for phase 1b/phase 2a non-oncology/obesity/AD clinical trials. (b) The commercial clinical prediction doesn't match the corresponding clinical readout for phase 2b/phase 3 clinical trials and phase 1b/phase 2a oncology/obesity/AD clinical trials. More precisely, a “SUCCESS commercial clinical prediction” is called correct if it is numerically better than (placebo-adjusted delta is preferred whenever there is a placebo control arm in the real clinical trial. There is no placebo control arm in many phase 1b/phase 2a real clinical trials so change from baseline value would be used instead) the SoC (The SoC could be pre-specified by the trial sponsor in the real head-to-head clinical trials. If there is no active control arm in the real clinical trials, then SoC would be pre-specified per bespoke instructions from specialist clients or per default selections by BioinvestGPT for our virtual head-to-head clinical trials to generate commercial clinical predictions) on registrational efficacy & toxicity endpoints (they are usually primary endpoints for phase 2b/phase 3 real clinical trials and secondary/exploratory endpoints for phase 1b/phase 2a real clinical trials). (c) The upward post-readout stock price movement corresponds to our OVERPRICED label to a company in the prediction, regardless of the actual readouts or our technical/commercial clinical predictions.
Pending Prediction
A prospective prediction is pending if there is no public announcement of the corresponding clinical readout as of today.
Current Prediction
A prospective prediction is pending if there is no public announcement of the corresponding clinical readout as of today.
Correct Prediction
Correct Prediction
Drug
drug
TBA
TBA
TBA2
TBA2
TBA3
TBA3
TBA4
TBA4
TBA5
TBA5
modality
Modality